S20-360 Targeted Cancer Therapy for the Treatment of Cancers That Have Mutations in the HAT1 Holoenzyme Complex Stanford researchers have developed a platform for identifying highly specific modulators of cancer-associated mutant Histone Acetyltransferase 1 (HAT1) holoenzyme complexes. Joshua Gruber Harry Gruber